

**Decrease in Left Ventricular Hypertrophy (LVH) in Heart Failure (HF) Patients after Changeover to Olmesartan from other Angiotensin II Receptor Blockers (ARBs).**

Shimoura H, et al. Heart Vessels. October, 2016.

- The renin-angiotensin system plays a key role in LVH, and LVH is an independent cardiovascular risk factor for HF patients.
- Effects of a changeover from other ARBs to olmesartan on LVH was evaluated in 64 patients with stable HF who had received ARBs other than olmesartan for more than 1 year.
- There was a significant decrease in LV mass from baseline over 12 months.

**LVH in HF patients was reduced by the changeover to olmesartan.**